Celltrion (068270) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
16 Nov, 2026Executive summary
3Q26 sales reached a quarterly record KRW1,575.5bn, up 53.1% YoY; operating profit hit a record KRW525.3bn, up 74.3%.
Young Products sales rose 74% YoY to KRW905.8bn, representing 67% of biologics sales; higher-margin products supported a 33.3% operating margin.
9M26 revenue was KRW4.114T, operating income KRW1.299T and net income KRW799.5bn, all higher YoY; Q3 net income declined YoY.
Commercialized biosimilars remained the core business as launches, late-stage biosimilar candidates and novel-modality programs broadened the portfolio.
Financial highlights
9M26 sales were KRW4.114T vs KRW2.832T YoY; Q3 sales were KRW1.576T vs KRW1.029T.
9M26 operating income was KRW1.299T vs KRW693.3bn; Q3 operating income was KRW525.3bn vs KRW301.4bn.
9M26 net income was KRW799.5bn vs KRW503.6bn, including KRW791.4bn attributable to parent shareholders; Q3 net income was KRW78.4bn vs KRW331.9bn.
Q3 gross profit was KRW955bn and gross margin 60.6%; operating margin was 33.3%, up from 29.3% in 3Q25.
9M26 basic EPS was KRW3,454 vs KRW2,158 YoY; diluted EPS was KRW3,440 vs KRW2,154.
Outlook and guidance
2026 revenue target was KRW5.3T; quarterly operating-income targets ranged from KRW300bn in Q1 to KRW600bn in Q4, with Q1–Q3 targets achieved.
4Q sales growth and margin improvement are expected to continue; Young Products’ revenue share is projected to exceed 70%, supported by product ramp-up and geographic expansion.
Five products launched in 2025 generated KRW388bn in 3Q26 and over KRW900bn in 9M26; ramp-up, new markets and indication expansion are expected to support growth through 4Q26 and 2027.
Songdo Plants 4 and 5 are planned to add 180,000 L of DS capacity, with expected investment of KRW1.2265T to expand internal production and support cost competitiveness and supply stability.
Portfolio plans include 18 commercialized biosimilars by 2030 and 41 by 2038, obesity-treatment IND filings, and CT-P77 preclinical results and IND submission by year-end.
Latest events from Celltrion
- Biosimilar growth and merger integration set an ambitious 2024 outlook, despite profit pressure.068270
Q4 2023 - Portfolio expansion, Zymfentra and AI-enabled R&D anchor the growth roadmap.068270
Investor presentation - Record 2Q24 sales and expanding biosimilar and novel-drug growth plans.068270
Investor presentation - Zymfentra and pipeline growth pair with CDMO expansion and higher shareholder returns.068270
Investor presentation - A broad biosimilar base supports an ADC and multispecific antibody pipeline advancing toward 2028 INDs.068270
Investor presentation - Targets combine rapid product expansion, higher profitability and 40% average shareholder returns.068270
Investor presentation - 2025 targets combine KRW 5T revenue with sharply lower COGS and stronger operating profit.068270
Investor presentation - Young products fuel 1Q growth as FY25 sales are forecast to reach KRW 5tn.068270
Investor presentation - Young-product growth lifted 3Q25 profit as biosimilar launches and capacity expanded.068270
Investor presentation